Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey , Edward E. Walsh , Robert W. Frenck , Ann R. Falsey , Nicholas Kitchin , Judith Absalon , Alejandra Gurtman , Stephen Lockhart , Kathleen M. Neuzil , Mark J. Mulligan , Ruth Bailey , Kena A. Swanson , Ping Li , Kenneth Koury , Warren V. Kalina , David Cooper , Camila R. Fontes-Garfias , Pei‐Yong Shi , Özlem Türeci , Kristin Tompkins , Kirsten E. Lyke , Vanessa Raabe , Philip R. Dormitzer , Kathrin U. Jansen , Uğur Şahin , William C. Gruber
2020 New England Journal of Medicine 2,665 citations

Abstract

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

Keywords

ImmunogenicityCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakComputational biologyMedicineBiologyImmunologyOutbreakAntigenInfectious disease (medical specialty)Internal medicine

Related Publications

Publication Info

Year
2020
Type
article
Volume
383
Issue
25
Pages
2439-2450
Citations
2665
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2665
OpenAlex

Cite This

Edward E. Walsh, Robert W. Frenck, Ann R. Falsey et al. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine , 383 (25) , 2439-2450. https://doi.org/10.1056/nejmoa2027906

Identifiers

DOI
10.1056/nejmoa2027906